User:Mr. Ibrahem/Betrixaban

Betrixaban, sold under the brand name Bevyxxa among others, was an anticoagulant used to prevent blood clots in veins in at risk adults, hospitalized for an illness. It has a higher rate of bleeding compared to enoxaparin. It was taken by mouth.

Common side effects include bleeding. Other side effects may include allergic reactions. Safety in pregnancy is unclear. It is a direct factor Xa inhibitor.

Betrixaban was approved for medical use in the United States in 2017; however, has been subsequently discontinued. It was refused approval in Europe in 2018 due to concerns regarding effectiveness and safety.